Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended March 31, 2014.
Q1 2014 Highlights and Recent Events
•The European Commission approved COMETRIQ® (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid cancer in January 2014.
Help employers find you! Check out all the jobs and post your resume.
